J&J Innovative Medicine

It’s been 30 years since the first World AIDS Day was recognized. Jens Van Roey, M.D., shares how a fateful diagnosis coincidentally that same year transformed him from a humble physician into a tireless champion for those afflicted with the disease.

Learn how the company’s consumer, pharmaceutical and medical devices businesses performed in the third quarter of 2018 in this snapshot of its latest earnings report.

For National Autism Awareness Month, Angela Andrews, a data manager at Janssen, shares her personal journey living and thriving with autism—and advocating for others just like her.

Johnson & Johnson has been instrumental in helping bring us closer to a TB-free world through its groundbreaking work with multidrug-resistant TB.

He may not wear a lab coat, but Johnson & Johnson (that’s his name!) is a member of the family, thanks to a conservation partnership between Xian Janssen and the Shaanxi Academy of Forestry Qinling Mountains Giant Panda Breeding Center. We catch up with the mischievous youngster on the anniversary of his adoption ceremony.

We sat down with the winner of the 2018 Dr. Paul Janssen Award for Biomedical Research to learn how his tireless cancer research efforts have helped revolutionize the way we treat the disease—and save lives.

Johnson & Johnson and Chinese company Legend Biotech have teamed up to work on a new form of treatment for the incurable blood cancer. We interview Dr. Sen Zhuang about the unique collaboration—and the promise it holds.

Tackling a triathlon isn’t for the faint of heart. But Mark van Ooij, an Associate Scientific Director for Janssen Vaccines & Prevention B.V., is doing just that—and he’s taking what he’s learned from his disease to propel him forward.

In the lead-up to the recent International AIDS Society Conference on HIV Science in the Netherlands, we sat down with Hanneke Schuitemaker, who’s hard at work on the holy grail of HIV research: a preventive treatment.

In this recap of Johnson & Johnson’s latest earnings report, you can learn how the company’s consumer, pharmaceutical and medical devices businesses performed in the second quarter of 2018.